Malignant Anal Neoplasm — Trials

Malignant Anal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 68
Recruiting: 34
Ph III recruiting: 2
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.1%
Trials / 1,000 deaths: 42.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05787535	HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor	unknown	Phase 1	17	HRYZ Biotech Co.INDUSTRY	1	Feb 2, 2024	clinicaltrials
NCT05122221	CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers	unknown	Phase 1	12	Corregene Biotechnology Co., LtdINDUSTRY	1	Jun 28, 2022	clinicaltrials